Top Markets
#1 Derive Derive +31.47%
#2 Audiera Audiera +14.41%
#3 Palladium Network Palladium Network +12.66%
#4 The Bitcoin Bull The Bitcoin Bull +10.64%
#5 Cross Cross +10.45%
#6 Gama Token Gama Token +9.20%
#7 Geodnet Geodnet +8.35%
#8 Humanity Humanity +7.62%
#9 Cap Cap +7.48%
#10 Starpower Starpower +7.47%
Coin of the day
Derive Derive
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Kazia Therapeutics Limited Kazia Therapeutics Limited

Kazia Therapeutics Limited

KZA
Clasificación en acciones #35840
Kazia Therapeutics Limited is a biotechnology firm specializing in oncology,... Kazia Therapeutics Limited is a biotechnology firm specializing in oncology, committed to developing innovative therapies for cancer. Its flagship product candidate, Paxalisib, is a brain-penetrant small molecule that inhibits the PI3K/Akt/mTor pathway and is currently being investigated as a potential treatment for glioblastoma. Additionally, the company is progressing EVT801, an investigational new drug aimed at combating various types of cancer. Established in 1994 and headquartered in Sydney, Australia, the entity was formerly known as Novogen Limited before adopting the name Kazia Therapeutics Limited in November 2017.
Precio por acción
$0.05207079
Última sincronización: 2023-11-15
Capitalización bursátil
$3.38M
Cambio (1 día)
0.13%
Cambio (1 año)
0.00%
País
AU
Comercio Kazia Therapeutics Limited (KZA)

Categoría

Healthcare
Ganancias de Kazia Therapeutics Limited (KZA)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Kazia Therapeutics Limited, gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Kazia Therapeutics Limited desde 2026 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
Not enough data for the provided dates.
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE